Table 1.

Demographic baseline characteristics of patients

Solid epithelial tumorsaMetastatic colorectal cancer
Dose escalation12 mg/kg9 mg/kg
Full analysis set20 (100)29 (100)13 (100)
Age (years)
 Median616368
 Min–max35–8135–8452–79
Sex (N, %)
 Female13 (65)14 (48)6 (46)
 Male7 (35)15 (52)7 (54)
Previous treatment for mCRC (N, %)
 BevacizumabNA18 (62)5 (39)
 IrinotecanNA25 (86)12 (92)
 OxaliplatinNA24 (83)10 (77)
Previous anti-EGFR treatment
 AnyNA29 (100)13 (100)
 Any cetuximab treatmentNA22 (76)11 (85)
 Any panitumumab treatmentNA13 (45)3 (23)
 More than one line of mAb treatmentNA13 (45)1 (8)
Previous treatment lines (N, %)b
 1–3NA15 (52)9 (69)
 >3NA14 (48)4 (31)
Metastatic sitesc
 LiverNA23 (79)8 (62)
 LungNA12 (41)7 (54)
 Lymph nodesNA6 (21)5 (39)
 OtherNA4 (14)2 (15)

Abbreviations: NA, not assessed; mCRC, metastatic colorectal cancer.

  • aOf 20 patients with solid epithelial tumors, 14 had colorectal cancer, 3 pancreatic cancer, 2 non–small cell lung cancer, and 1 spinal chordoma.

  • bIncluding antitumor compounds aflibercept, sorafenib, ramucirumab, carlumab, deforolimus, ganitumab, trebananib, and cediranib.

  • cMultiple nominations of metastatic sites identified as target lesions per patient possible.